Ichiro Takasaki

Dr. Ichiro Takasaki

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JKJi-Ye Kee
Ji-Ye Kee
AIAya Ito
Aya Ito
SHShozo Hojo
Shozo Hojo
IHIsaya Hashimoto
Isaya Hashimoto
YIYoshiko Igarashi
Yoshiko Igarashi
KKKeiichi Koizumi
Keiichi Koizumi
Inhibition of metastasis through upregulation of immune surveillance is a major purpose of chemokine gene therapy. In this study, we focused on a membrane-bound chemokine CXCL16, which has shown a correlation with a good prognosis for colorectal cancer (CRC) patients. We generated a CXCL16-expressing metastatic CRC cell line and identified changes in TNF and apoptosis-related factors. To investigate the effect of CXCL16 on colorectal liver metastasis, we injected SL4-Cont and SL4-CXCL16 cells into intraportal vein in C57BL/6 mice and evaluated the metastasis. Moreover, we analyzed metastatic liver tissues using flow cytometry whether CXCL16 expression regulates the infiltration of M1 macrophages. CXCL16 expression enhanced TNF-α-induced apoptosis through activation of PARP and the caspase-3-mediated apoptotic pathway and through inactivation of the NF-κB-mediated survival pathway. Several genes were changed by CXCL16 expression, but we focused on IRF8, which is a regulator of apoptosis and the metastatic phenotype. We confirmed CXCL16 expression in SL4-CXCL16 cells and the correlation between CXCL16 and IRF8. Silencing of IRF8 significantly decreased TNF-α-induced apoptosis. Liver metastasis of SL4-CXCL16 cells was also inhibited by TNF-α-induced apoptosis through the induction of M1 macrophages, which released TNF-α. Our findings suggest that the accumulation of M1 macrophages and the enhancement of apoptosis by CXCL16 might be an effective dual approach against CRC liver metastasis. Collectively, this study revealed that CXCL16 regulates immune surveillance and cell signaling. Therefore, we provide the first evidence of CXCL16 serving as an intracellular signaling molecule.

1 April 2018 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
ITIchiro Takasaki
Ichiro Takasaki
AWAi Watanabe
Ai Watanabe
MYMasafumi Yokai
Masafumi Yokai
YWYurie Watanabe
Yurie Watanabe
DHDaichi Hayakawa
Daichi Hayakawa
TKTakashi Kurihara
Takashi Kurihara
Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors are present in the spinal dorsal horn and dorsal root ganglia, suggesting an important role of PACAP signaling systems in the modulation of spinal nociceptive transmission. Previously, we found that intrathecal (i.t.) injection of PACAP or maxadilan, a selective PACAP type I (PAC1) receptor agonist, induced transient aversive responses followed by a long-lasting mechanical allodynia in mice, suggesting that PACAP-PAC1 receptor systems are involved in chronic pain and that selective PAC1 antagonists may become a new class of analgesics. Although several PAC1 antagonists, such as PACAP 6-38, have been reported, all of them are peptide compounds. In the present study, we identified new small-molecule antagonists of the PAC1 receptor using in silico screening and in vitro/vivo pharmacological assays. The identified small-molecule compounds, named PA-8 and PA-9, dose-dependently inhibited the phosphorylation of CREB induced by PACAP in PAC1-, but not VPAC1- or VPAC2-receptor-expressing CHO cells. PA-8 and PA-9 also dose-dependently inhibited PACAP-induced cAMP elevation with an IC50 of 2.0 and 5.6 nM, respectively. In vivo pharmacological assays showed that i.t. injection of these compounds blocked the induction of PACAP-induced aversive responses and mechanical allodynia in mice. In contrast, the compounds when administered alone exerted neither agonistic nor algesic actions in the in vitro/vivo assays. The compounds identified in the present study are new and the first small-molecule antagonists of the PAC1 receptor; they may become seed compounds for developing novel analgesics.

1 February 2019 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
ITIchiro Takasaki
Ichiro Takasaki
KNKoji Nakamura
Koji Nakamura
ASAyaka Shimodaira
Ayaka Shimodaira
AWAi Watanabe
Ai Watanabe
HNHuy Du Nguyen
Huy Du Nguyen
TKTakashi Kurihara
Takashi Kurihara
We recently developed PA-8, a novel small-molecule antagonist of PACAP type 1 (PAC1) receptor. In the present study, we examined whether PA-8 was effective against formalin-induced inflammatory pain in mice. Both intrathecal and oral administration of PA-8 resulted in the dose-dependent attenuation of the second phase of formalin-induced nociceptive responses. PA-8 also inhibited c-fos upregulation in the ipsilateral dorsal horn of the spinal cord. The results suggested that PACAP-PAC1 receptor signaling system in the spinal cord were primarily involved in the transmission of inflammatory pain, and PA-8 could be useful for the development of novel analgesics for treating inflammatory pain.

1 January 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ITIchiro Takasaki
Ichiro Takasaki
HOHaruna Ogashi
Haruna Ogashi
TOTakuya Okada
Takuya Okada
ASAyaka Shimodaira
Ayaka Shimodaira
DHDaichi Hayakawa
Daichi Hayakawa
NTNaoki Toyooka
Naoki Toyooka

1 November 2013 in Behavioural Brain Research
Verified
Journal Article
Closed access
ITIchiro Takasaki
Ichiro Takasaki
KOKyohei Oose
Kyohei Oose
YOYuki Otaki
Yuki Otaki
DIDaisuke Ihara
Daisuke Ihara
MFMamoru Fukuchi
Mamoru Fukuchi
MTMasaaki Tsuda
Masaaki Tsuda

29 January 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ITIchiro Takasaki
Ichiro Takasaki
AWAi Watanabe
Ai Watanabe
TOTakuya Okada
Takuya Okada
DKDaisuke Kanayama
Daisuke Kanayama
RNRyota Nagashima
Ryota Nagashima
NTNaoki Toyooka
Naoki Toyooka